JUBLPHARMA - IntraDay Trade Analysis with Live Signals

Last Updated Time : 20 Dec 25, 07:03 am

IntraDay Trade Rating: 2.9

📊 Analysis: JUBLPHARMA is trading at ₹1,073, slightly below its 50 DMA (₹1,093) but above the 200 DMA (₹1,068), showing mixed technical signals. RSI at 42.8 indicates neutral-to-weak momentum, while MACD (-12.9) confirms bearish bias. Current volume (69,285) is lower than average (77,294), suggesting limited intraday participation. The stock is near support levels around ₹1,065–₹1,070 but faces resistance at ₹1,085–₹1,095.

💡 Optimal Buy Price: ₹1,065–₹1,070 if support holds intraday.

🎯 Profit Exit Levels: ₹1,085–₹1,095 (short-term resistance).

🛑 Stop-Loss: ₹1,055 to protect against downside risk.

⏱️ If Already Holding: Exit near ₹1,085–₹1,095 if momentum stalls or RSI fails to recover. If price breaks below ₹1,055 with volume confirmation, consider closing positions to avoid deeper losses.

Positive

• 📈 EPS of 1.15 ₹ supports earnings visibility, though modest.
• 💹 ROE (1.04%) and ROCE (2.91%) remain positive, albeit low.
• 🌍 DII holding increased by 1.01%, showing domestic institutional confidence.
• 💰 Dividend yield of 0.47% provides shareholder returns.
• 📊 Debt-to-equity ratio of 0.02 reflects strong financial stability.

Limitation

• ⚠️ Current price below 50 DMA, reflecting weak short-term trend.
• 📉 RSI and MACD show bearish momentum, limiting upside intraday.
• 🔻 Volume below average, reducing breakout strength.

Company Negative News

• 📉 Quarterly PAT dropped sharply from 4.10 Cr. to -48 Cr., showing significant earnings pressure.
• ⚠️ Quarterly profit variation at -436% highlights severe volatility.
• 🔻 FII holding decreased by 0.84%, showing reduced foreign investor confidence.

Company Positive News

• 📊 DII holding increased by 1.01%, reflecting domestic institutional support.
• 💰 Dividend yield of 0.47% and low debt-to-equity ratio highlight financial resilience.

Industry

• 🏭 Industry PE at 30.6, but JUBLPHARMA’s P/E is not meaningful due to negative earnings.
• 📈 52-week index performance at 60.6% shows sector resilience despite volatility.

Conclusion

⚖️ JUBLPHARMA presents weak intraday potential due to negative earnings and bearish technical indicators. While low debt and dividend yield provide stability, sharp PAT decline and reduced foreign investor confidence limit upside. Tactical entries near ₹1,065–₹1,070 with exits around ₹1,085–₹1,095 are possible, but a strict stop-loss at ₹1,055 is essential to manage risk.

Would you like me to extend this into a peer benchmarking overlay with other pharma sector stocks (like Sun Pharma, Cipla, Dr. Reddy’s) to identify relative intraday strength and rotation opportunities?